The new agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare’s immuno-diagnostic portfolio, to enable patient selection and monitoring in immunotherapy trials. Telix...
With the rights to human iPSC technology, SCG can mass-produce off-the-shelf natural killer cell therapy, making it more affordable and accessible to patients. Singapore-based SCG Cell Therapy Pte...
On the 100th anniversary of Lipiodol’s introduction as a contrast agent in radiology, research is turning to the role of Lipiodol TACE (cTACE) in combination treatments for Hepatocellular...
A collaboration between Hummingbird Bioscience and MD Anderson will serve to investigate and evaluate Hummingbird’s HMBD-002 VISTA antagonist antibody. Hummingbird Bioscience, an innovative...
Researchers from Duke-NUS Medical School in Singapore and Monash University in Australia have created EpiMogrify, a computer model that effectively predicts molecules required for stem cell...
Researchers from the National Cancer Centre Singapore (NCCS) discover a genetic marker that identifies patients of aggressive blood cancer likely to respond well to a novel immunotherapy treatment...
Cancer drug developed in Singapore by Duke-NUS Medical School and the Agency for Science, Technology and Research (A*STAR) with applications in cancer immunotherapy takes its first steps into the...
Roche’s Tecentriq® in combination with chemotherapy gains approval from Singapore’s Health Sciences Authority (HSA). The global provider of pharmaceuticals and cancer treatments, Roche,...
Biofourmis recently acquired Gaido Health from Takeda Digital Ventures, building on its oncology portfolio, to improve the care experience for cancer patients and providers. Gaido Health—a Los...
Interview with Dr Choo Su Pin to shed light on a new generation of therapies that could improve the prognosis of liver cancer patients. Liver cancer is the sixth most common cancer worldwide, which...
First incorporated in 2018, CytoMed Therapeutics is a start-up spin-off from the Agency for Science, Technology and Research (A*STAR). Its main focus is to leverage on their proprietary technologies...
Presenting their results at the ESMO Asia Congress in 2019, researchers of the IMbrave150 study show for the first time in a decade a new class of treatment for hepatocellular carcinoma. The study...
